Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report

Metastatic prostate cancer remains a challenge for clinicians. Metastases involve mainly the bone compartment and can manifest as oligometastatic disease. In this setting, the role of metastasis-directed therapies (MDT) including surgery and/or stereotactic body radiotherapy is currently evaluated. Visceral metastases are less common and have very poor prognosis in mPC. Whether treating isolated visceral metastases such as liver metastases with MDT could increase the prognosis remains unknown. We report the management of a prostate cancer patient who progressed on androgen deprivation therapy with apparition of two liver metastases. We describe the feasibility of combining MDT with abiraterone acetate and prednisone in a patient with metastatic castration-resistant prostate cancer. MDT allowed the interruption of abiraterone acetate, preventing cumulative toxicity of this agent.

Automated summary

Metastatic prostate cancer remains challenging for clinicians, with the focus on bone metastases and the potential of metastasis-directed therapies. Less common visceral metastases have a poor prognosis, and the effectiveness of MDT on visceral metastases such as liver metastases remains unknown. The case study explored combining MDT with drug therapy in a patient with metastatic castration-resistant prostate cancer and highlighted the potential benefits of this approach in managing toxicities.